Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Peking University People's Hospital: Clinical Trials & FDA Approval Profile

Peking University People's Hospital (Global / Institutional) sponsors 135 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 55 active protocols (29 recruiting now), 15 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.7%
Median Closed Enrollment vs National (145 pts)74 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Peking University People's Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)135
Active Pipeline (Recruiting Now)55 (29)
Completed vs Stopped Early15 / 5 (3.7%)
Median Closed Actual Enrollment74 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Peking University People's Hospital
Hospital Research SiteLocationShared Protocols
Peking University People's HospitalBeijing, Beijing Municipality52
Peking University First HospitalBeijing, Beijing Municipality6
Peking University Third HospitalBeijing, Beijing Municipality5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Peking University People's Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07796516Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Peking University People's Hospital Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI